<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365142</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-PRGF/ART</org_study_id>
    <secondary_id>2011-006036-23</secondary_id>
    <nct_id>NCT02365142</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma</brief_title>
  <acronym>CMM-PRGF/ART</acronym>
  <official_title>Phase I/II. Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma(PRGF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet
      richa plasma (PRGF) in patients with knee osteoarthritis.

      Patients and methods

      Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19
      patients for each group. The investigators compare the intraarticular injection of against
      the administration of two different doses of mesenchymal stem cells with hialuronic acid
      according to the following scheme:

        1. Group A: 3 intra-articular injections of platelet rich plasma (PRGF®) separated by 7
           days.

        2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7
           days and one with Mesenchimal stems cells. Intra-articular injection of 100 million
           autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile
           small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by
           an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed
           with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.

      In addition the investigators assess the response to intra-articular infusion of CMM
      analyzing the following parameters:

        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.

        -  Radiographic (baseline and 12 months from treatment): Femorotibial space.

        -  Radiographic using MRI (baseline and 12 months from treatment): by assessing the number
           location of the lesions , cartilage thickness , signal intensity , subchondral bone
           alteration , volume and WORMS and dGEMRIC protocols.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet
      richa plasma (PRGF®) in patients with knee osteoarthritis.

      Patients and methods

      Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19
      patients for each group. The investigators compare the intraarticular injection of against
      the administration of two different doses of mesenchymal stem cells with hialuronic acid
      according to the following scheme:

        1. Group A: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7
           days.

        2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7
           days and one with Mesenchimal stem cell. Intra-articular injection of 100 million
           autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile
           small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by
           an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed
           with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.

      The autologous mesenchymal stem cells are obtained from the iliac crest under local
      anesthesia and sedation. They are cultured ex vivo The primary endpoint is safety and
      feasibility. The investigators registered the occurrence of complications and / or adverse
      effects during the study.

      In addition the investigators assess the response to intra-articular infusion of CMM
      analyzing the following parameters:

        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.

        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.

        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the
           number location of the lesions , cartilage thickness , signal intensity , subchondral
           bone alteration , volume and WORMS and dGEMRIC protocols.

      All patients met the following inclusion and exclusion criteria:
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Visual analogue scale (VAS) Baseline Visual analogue scale (VAS)</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline Visual analogue scale (VAS) prior to the initial dose on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline value of knee injury and osteoarthritis outcome score (Koos).</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</measure>
    <time_frame>Day 1</time_frame>
    <description>Universities Osteoarthritis Index score (WOMAC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline SF-36 value</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline euroquol 5D value</measure>
    <time_frame>Day 1</time_frame>
    <description>Pretreatment euroquol 5D value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lequesne index</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention on day 1 Lequesne index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline femorotibial distance</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention femoritibial distance on rosenberg x-ray view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Follow up (up to 12 months)</time_frame>
    <description>Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events During the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Visual analogue scale (VAS) at on month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue scale (VAS) at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale (VAS) at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual analogue scale (VAS) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</measure>
    <time_frame>3 Months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>100 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>100 million Bone marrow mesenchimal stem cells with PRGF</description>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich plasma (PRGF)</intervention_name>
    <description>3 injections of PRGF</description>
    <arm_group_label>Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 40 and 80 year old

          -  Bad results with previous hyaluronic acid injection

          -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American
             College of Rheumatology)

          -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS)

          -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2

          -  Body mass index between 20 and 35 kg/m2

          -  Ability to follow during the study period

        Exclusion Criteria:

          -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees

          -  Previous diagnosis of polyarticular disease

          -  Severe mechanical deformation

          -  Arthroscopy during the previous 6 months

          -  Intraarticular infiltration of hyaluronic acid in the last 6 months

          -  Systemic autoimmune rheumatic disease

          -  Poorly controlled diabetes mellitus

          -  Blood dyscrasias

          -  Immunosuppressive or anticoagulant treatments

          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study

          -  NSAID therapy within 15 days prior to inclusion in the study

          -  Patients with a history of allergy to penicillin or streptomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Lamo-Espinosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Blanco, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla-León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departamento Cirugía Ortopédica y Traumatología. Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla</url>
    <description>University clinic of navarre trial information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Mesenchimal stem cell</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

